Eligibility for Ovarian Cancer Treatment in Cuba

Understanding Eligibility

Ovarian cancer treatment eligibility in Cuba is determined through a comprehensive medical review of each patient's diagnosis, staging, histological subtype, molecular profile (BRCA/HRD status), prior treatments, and overall health. Cuba's oncology team evaluates each case individually.

Medical Review Process

The medical review requires:

• Pathology reports — Biopsy or surgical pathology confirming ovarian cancer with histological type (high-grade serous, low-grade serous, endometrioid, clear cell, mucinous) and grade. Surgical report from cytoreductive surgery if performed, including extent of debulking (residual disease). • Staging — FIGO staging based on surgical findings and pathology. • Imaging studies — CT chest/abdomen/pelvis, MRI pelvis if needed. PET-CT for suspected recurrent disease. • Genetic testing — BRCA1/BRCA2 mutation testing and HRD (homologous recombination deficiency) testing. These are critical for treatment planning (PARP inhibitor eligibility) and family risk assessment. • Tumor markers — CA-125 baseline and trend (for monitoring treatment response). • Treatment history — Prior chemotherapy regimens (drugs, cycles, dates, response), surgery details, and any targeted/biologic therapy. • Blood work — Recent complete blood count, liver/kidney function, CA-125. • General health assessment — Medical history including comorbidities, current medications, and overall physical status (surgical fitness).

The gynecologic oncology and medical oncology team reviews these documents to confirm staging and design an individualized treatment plan.

Who Benefits Most

Ovarian cancer treatment in Cuba may be particularly valuable for:

• Patients requiring cytoreductive surgery — Cuba has experienced gynecologic oncology surgeons capable of complex debulking procedures. • Patients seeking a second opinion — Independent review of diagnosis, staging, and treatment plan. • Patients seeking conventional treatment at competitive costs — Standard oncology care at lower costs than many private systems. • Patients with recurrent disease — Seeking additional treatment options including platinum re-challenge, non-platinum chemotherapy, and targeted therapy. • Patients interested in experimental immunotherapy — Those with EGFR-expressing tumors who may be eligible for CIMAher clinical trials. • Patients from countries with limited gynecologic oncology infrastructure.

The medical team provides an honest assessment of treatment options for each individual case.

Preparing Your Medical Records

To begin the eligibility review:

• Surgical pathology reports (histological type, grade, extent of debulking) • FIGO staging documentation • Genetic testing results (BRCA1/BRCA2, HRD) if available • Imaging on CD/DVD (CT, MRI, PET-CT) • Surgical operative reports • Complete chemotherapy history (drugs, cycles, response) • Recent blood work including CA-125 trend • Current medication list

Documents should ideally be in Spanish or English. SMC Salud assists with translation. The review takes 5-10 business days, after which a treatment proposal with eligibility confirmation and transparent cost estimate is provided.